Previous 10 | Next 10 |
Jazz Pharmaceuticals (NASDAQ: JAZZ ) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. The consensus EPS Estimate is $3.16 (+6.0% Y/Y) and the consensus Revenue Estimate is $466.55M (+4.9% Y/Y). Over the last 2 years, jazz has beaten EPS estimates ...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
DUBLIN , April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of the financial markets. Company management will host a live audio webcast...
The U.S. Department of Justice has reached agreement with Jazz Pharmaceuticals ( JAZZ +1.3% ), Alexion Pharmaceuticals ( ALXN -0.2% ) and Lundbeck, LLC to resolve allegations that they illegally paid Medicare or Civilian Health and Medical Program copays for their own products through ...
A Phase 3 clinical trial evaluating Jazz Pharmaceuticals' (NASDAQ: JAZZ ) JZP-258 for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult patients with narcolepsy met the primary endpoint . More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, R...
DUBLIN , March 26, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the global, double-blind, placebo-controlled, randomized-withdrawal, multicenter Phase 3 study evaluating the efficacy and safety of JZP-258 for the tre...
The FDA has approved Jazz Pharmaceuticals' (NASDAQ: JAZZ ) Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). More news on: Jazz Pharmaceuticals plc, Healthcare stocks news, Rea...
DUBLIN , March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi ™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with na...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Interest rates are back in the spotlight with a Federal Reserve interest rate decis...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...